Characteristics of clinical studies.

Table 3: Characteristics of clinical studies.

Author, year	Study Design	Population characteristics	Population (total n)	Follow-up (weeks)	Interventions		Evaluated variables
Author, year	Study Design	Population characteristics	Population (total n)	Follow-up (weeks)	Delivery vehicle	Dosage given to the intervention group²	Evaluated variables
Chatree, et al. 2020 [21]	Randomized double-blind placebo-controlled clinical trial	Obesity	30	8	Capsule	150	BMI, weight, circumferences, fat body mass, blood glucose, insulin, HOMA-IR, TC, TG, HDL, LDL, BP
Katanasaka, et al. (2020) [22]	Cohort study (prospective observational study)	Obesity with MetS	6	12	Tea	1000	BMI, weight, circumferences, blood glucose, insulin, HOMA-IR, TC, TG, HDL, LDL, BP
Chen, et al. (2016) [23]	Randomized double-blind placebo-controlled clinical trial	Obesity	77	12	Capsule	2576	BMI, weight, circumferences, blood glucose, insulin, HbA1c, HOMA-IR, TC, TG, HDL, LDL, BP
Nogueira, et al. (2016) [24]	Randomized double-blind placebo-controlled clinical trial	Obesity with CV	20	4	Capsule	1500	BMI, weight, circumferences, TNF, IL-6, CRP, blood glucose, insulin, HOMA-IR, TC, TG, HDL, LDL, BP, oxidative stress
Suliburska, et al. (2012) [25]	Randomized double-blind placebo-controlled clinical trial	Obesity	46	12	Capsule	379	BMI, circumferences, blood glucose, TC, TG, HDL, LDL, BP, oxidative stress
Bogdanski, et al., (2012) [26]	Randomized double-blind placebo-controlled clinical trial	Obesity with CV	56	12	Capsule	379	BMI, circumferences, TNF, CRP, blood glucose, insulin, HOMA-IR, TC, TG, HDL, LDL, BP, oxidative stress
Basu, et al. (2011) [27]	Randomized single-blind placebo-controlled clinical trial	Obesity with MetS	35	8	Capsule and Tea	870 (capsule) and 928 (tea)	Circumferences, IL-6, blood glucose, HbA1c, TC, TG, HDL, LDL, BP
HSU, et al. (2011) [28]	Randomized double-blind placebo-controlled clinical trial	Obesity with T2DM	68	16	Capsule	1500	BMI, weight, circumferences, blood glucose, insulin, HbA1c, HOMA-IR, TC, TG, HDL, LDL, BP
Basu, et al. (2010) [29]	Randomized single-blind placebo-controlled clinical trial	Obesity with MetS	35	8	Capsule and Tea	870 (capsule) and 928 (tea)	BMI, weight, circumferences, fat body mass, blood glucose, HbA1c, HOMA-IR, TC, TG, HDL, LDL, BP
Mielgo-Ayuso et al. (2014) [30]	Randomized double-blind placebo-controlled clinical trial	Obesity	83	12	Capsule	300	BMI, weight, circumferences, fat body mass, lean body mass, CRP, blood glucose, insulin, HOMA-IR, TC, TG, HDL, LDL
Huang, et al. (2018) [31]	Randomized double-blind placebo-controlled clinical trial	Obesity with CV	73	12	Capsule	1500	BMI, weight, circumferences, blood glucose, insulin, TC, TG, HDL, LDL

¹Mean ± SD or BMI interval. milligrams/day; BMI: Body Mass Index; T2DM: Type 2 Diabetes Mellitus; CV: Cardiovascular Disease; MetS: Metabolic Syndrome; TNF: Tumor Necrosis Factor; IL-6: Interleukin 6; CRP: C-reactive Protein; HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; HbA1c: Glycated Hemoglobin; TC: Total Cholesterol; TG: Triglycerides; HDL: High-Density Lipoprotein Cholesterol; LDL: Low-Density Lipoprotein Cholesterol; FFA: Free Fatty Acids; BP: Blood Pressure